Karolinska Development AB receives additional guarantee commitments in ongoing rights issue

Core Viewpoint - Karolinska Development AB has announced additional guarantee commitments of approximately 20 MSEK in its ongoing rights issue, bringing the total to approximately 115.2 MSEK, which covers about 57% of the rights issue volume [2][3]. Group 1: Rights Issue Details - The rights issue was resolved by the Board of Directors on December 1, 2025, and approved by the extraordinary general meeting on January 8, 2026, with a subscription period running until January 27, 2026 [2]. - The total rights issue amount is approximately 202.6 MSEK before issue costs [2]. - The Intermediate Guarantee covers the interval from approximately 47% to 57% of the rights issue, amounting to approximately 115.2 MSEK [3]. Group 2: Guarantee Commitments - Previously agreed guarantee commitments have increased from approximately 95.2 MSEK to approximately 115.2 MSEK [3]. - The guarantee commitments are not secured through bank guarantees or similar arrangements [5]. - A cash guarantee fee of 13% or a fee of 15% in newly issued shares will be paid for the Intermediate Guarantee [4]. Group 3: Shareholder Implications - Investors acquiring a shareholding of 10% or more of the total votes in the Company must notify the Inspectorate of Strategic Products prior to the investment [6]. - Any guarantee commitments that require approval under the Swedish Screening of Foreign Direct Investments Act are conditional upon obtaining such approval [6][19]. Group 4: Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing medical innovations [10]. - The company aims to build companies around leading scientists and management teams, co-funded by international investors [11]. - Karolinska Development has a portfolio of eleven companies targeting innovative treatments for serious diseases [12].